Merck KGaA (FRA:MRK) received a €100.00 ($116.28) price objective from stock analysts at J P Morgan Chase & Co in a report issued on Wednesday, November 1st. The brokerage currently has a “neutral” rating on the healthcare company’s stock. J P Morgan Chase & Co’s price target indicates a potential upside of 11.37% from the stock’s previous close.
A number of other equities research analysts also recently issued reports on the stock. UBS AG set a €120.00 ($139.53) target price on shares of Merck KGaA and gave the company a “buy” rating in a report on Monday, October 23rd. Warburg Research set a €116.00 ($134.88) price objective on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Friday, July 7th. equinet AG set a €112.00 ($130.23) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, August 31st. Societe Generale set a €103.00 ($119.77) price objective on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Tuesday, September 5th. Finally, Goldman Sachs Group, Inc. (The) set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Wednesday, September 6th. Thirteen research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Merck KGaA currently has an average rating of “Hold” and an average target price of €108.61 ($126.29).
Shares of Merck KGaA (MRK) opened at €89.79 ($104.41) on Wednesday. Merck KGaA has a twelve month low of €89.00 ($103.49) and a twelve month high of €115.00 ($133.72).
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/12/merck-kgaa-mrk-pt-set-at-100-00-by-j-p-morgan-chase-co.html.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.